Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Market Cap	26.41B
Revenue (ttm)	3.96B
Net Income (ttm)	513.69M
Shares Out	576.66M
EPS (ttm)	2.21
PE Ratio	20.68
Forward PE	n/a
Dividend	5.69 (12.37%)
Ex-Dividend Date	Jul 31, 2025

Volume	555,051
Average Volume	308,144
Open	46.42
Previous Close	46.42
Day's Range	45.30 - 46.74
52-Week Range	32.62 - 67.30
Beta	-0.07
RSI	40.19
Earnings Date	Nov 28, 2025

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 4,861
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6887

Financial Performance

In 2024, Sunshine Lake Pharma's revenue was 3.72 billion, a decrease of -40.84% compared to the previous year's 6.29 billion. Earnings were 482.71 million, a decrease of -75.78%.

Financial numbers in CNY